Chemoprotection against fractionated radiation exposures with WR-2721: skin injury

These studies extend the analysis of the potential application of WR-2721 [S-2-(3-aminopropylamino)ethylphosphorothioic acid] to radiation therapy by determining the ability of the drug to protect mice against hair loss induced by multiple exposures to radiation. In the two mouse strains tested, RFM and BALB/c, the relatively low drug dose used (200 mg/kg) protected the mice against hair loss from single exposures by factors of 1.67 and 1.73. The dose necessary to produce a given level of hair loss (ED50) increases with increasing number of fractions. The ED50 increases as N/sup 0.52/ and N/sup 0.59/ in the two strains of mice when they are not drug-treated, but as N/sup 0.39/ and N/sup 0.50/ in mice that are drug-treated. Thus, the protective effectiveness of WR-2721 decreases with increasing numbers of fractions, but the drug is still able to give a dose-modifying factor of about 1.25 when the total exposure is given as a series of 9 or 10 fractions. WR-2721 appears to offer the possibility of improving the efficiency of radiotherapy under clinical conditions